Non-tech. summaries 2015: projects on sensory organs
Projects granted during 2015 that have a primary purpose of basic research: sensory organs (skin, eyes and ears).
Documents
Details
This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2015 with a primary purpose of basic research: sensory organs (skin, eyes and ears).
The following projects were granted:
-
therapy in mitochondrial optic neuropathy (optic neuropathy, mitochondria, retinal ganglion cells)
-
corneal stromal stem cells for corneal regeneration (cornea, amniotic membrane, stem cells, ocular surface, wound healing)
-
maximising the success and effects of glaucoma filtration surgery (glaucoma, wound healing, transplant, angiogenesis)
-
protection and repair of the retina & optic nerve (glaucoma, macular degeneration, optic nerve)
-
novel therapeutic targets in ocular disease (VEGF, diabetes, AMD, neuroprotection, neovascularisation)
-
regulation of keratinocyte proliferation and differentiation (skin, mouth, cancer, inflammation, stem cells)
-
the contribution of mast cells and their mediators in inflammatory skin diseases (mast cells, psoriasis, atopic dermatitis, allergy)
-
protecting and repairing the injured eye (eye, nerves, trauma, neuron, death)
-
protecting and repairing injured retinal cells in glaucoma (glaucoma, retinal ganglion cell, trabecular meshwork, scarring)
-
the impact of context on rat whisking behaviour (vibrissa, whisking, tactile, attention, neuroethology)
-
control of vascular behaviour in the retina (retinal vasculature, angiogenesis, inflammation)
-
retinal development and degeneration in zebrafish (zebrafish, retinal degeneration, disease mechanisms, treatment)
-
investigating epithelial maintenance, pathogenesis and wound healing (epithelium, stem cell, cancer, infection, wound healing)
-
early diagnosis and therapy through the eye (retina, neurodegeneration, neuroprotection, imaging, treatment)
-
functions of novel lipids in wounded skin (wound healing, lipids, skin disease)
-
novel biologics for treating ocular disease (binding domains, auto-immune eye disease)